Lionel Adès, Fabien Le Bras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, François Dreyfus, Virginie Eclache, Jacques Delaunay, Didier Bouscary, Sorin Visanica, Pascal Turlure, Agnès Guerci Bresler, Marie-Paule Cabrol, Anne Banos, Michel Blanc, Norbert Vey, Alain Delmer, Eric Wattel, Sylvie Chevret, Pierre Fenaux. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. haematol [Internet]. 2012Jan.31 [cited 2024May2];97(2):213-8. Available from: https://haematologica.org/article/view/6209